Equity Member Jeffrey E. Nicoson in the firm's Memphis office was honored to be a guest presenter at MedMarc's recent webinar titled, "Claims 2024: What’s Happening and What You Need to Know." The panel covered supply chain management, challenges related to international supply chains, and the implications of the Loper Bright case. They also examined the effects of recent legal rulings, including the Zantac decision, and how political and advocacy group influences might impact FDA decisions. Lastly, the discussion ended with a crystal ball outlook of uncertainty which included the potential effects of litigation financing on plaintiff attorneys and mass torts and was optimistic about the use of AI in detecting fraud and inconsistencies in clinical trials. Congratulations, Jeff! Read more here: https://lnkd.in/dEhkYnfj
Leitner, Williams, Dooley & Napolitan, PLLC’s Post
More Relevant Posts
-
Our latest edition of Antitrust in focus, edited by David Higbee and Dominic Long, tells you about the U.K.’s new consumer, antitrust and digital markets regime, scrutiny of serial acquisitions and below-threshold deals, and the U.S. antitrust agencies’ focus on health care. We also report on an EU fine for cross-border trade restrictions, the European Commission’s antitrust position on labor market practices, updates on sustainability initiatives and more.
-
This weekend, rewatch the #SaveBayhDole videos from friends and supporters of The Bayh-Dole Coalition. These videos detail the real-life significance of the Bayh-Dole Act and the devastation that would result from undermining such an important piece of legislation. "[The march-in proposal] is being done under the guise of lowering drug costs. It can't possibly lower drug prices, but it can lower innovation, so it's a very real threat... That's one thing the Bayh-Dole Coalition is bringing to people's attention in the media, on Capitol Hill and even the administration -- that this is a policy blunder, it's bad law, and it's a disaster for American innovation." - Bayh-Dole Coalition Executive Director Joseph Allen "[The march-in framework] puts our inventions at a disadvantage in a very competitive market space." - Emory University OTT Executive Director Todd Sherer "It's not good for the taxpayer if all that research stays in the lab, rather than making it out to benefit the rest of us." - AUTM Foundation Chair Laura Schoppe Watch these videos and more below: https://lnkd.in/eM7Tr-FD #BayhDole #SaveBayhDole #policy #law #legislation #Congress #research #technology #techtransfer #science #medicine
-
Webinar: Hot Topics in Healthcare Antitrust. #nysbahls #healthlaw
Join the Hispanic National Bar Association’s Health and Life Sciences Law Committee for an engaging discussion on antitrust enforcement in the life sciences and healthcare sectors. Panelists will discuss a range of hot topics, including merger control, scrutiny of Pharmacy Benefit Managers, pricing practices, and other competition-related challenges. RSVP: https://lnkd.in/eMPyekuG Adam Acosta Alexis Gilman White & Case LLP
-
-
If you work or invest in healthcare companies and this is not yet on your radar, you need to click below. #privateequity in #healthcare is in the crosshairs of the FTC. All stakeholders should be aware of the published guidelines and should be working with an #antitrust team that can help navigate these waters. Let me know if you want to connect because this issue is not going to just go away.
#Antitrust attorneys David Kully, Kenneth L. Racowski, Bill Katz and Anna Hayes recently contributed to a Dallas Business Journal article on the Federal Trade Commission's scrutiny of #privateequity in #healthcare. A public workshop hosted by the FTC shed light on concerns about private equity's influence on patient care and regulatory scrutiny of consolidation strategies, reaffirming antitrust enforcers' commitment to monitoring market concentration, care incentives and #investment approaches. Read here:
Antitrust Enforcers Reaffirm Focus on Private Equity in Healthcare at Public Workshop | Insights | Holland & Knight
hklaw.com
-
The FDA has kicked off the new year by publishing two highly-anticipated draft guidance documents concerning artificial intelligence, which we discuss in this Covington & Burling LLP alert: https://okt.to/8omi3a
-
-
Our latest edition of Antitrust in focus, edited by David Higbee and Dominic Long, tells you about the U.K.’s new consumer, antitrust and digital markets regime, scrutiny of serial acquisitions and below-threshold deals, and the U.S. antitrust agencies’ focus on health care. We also report on an EU fine for cross-border trade restrictions, the European Commission’s antitrust position on labor market practices, updates on sustainability initiatives and more.
Antitrust in focus May 2024
aoshearman.smh.re
-
Our latest edition of Antitrust in focus, edited by David Higbee and Dominic Long, tells you about the U.K.’s new consumer, antitrust and digital markets regime, scrutiny of serial acquisitions and below-threshold deals, and the U.S. antitrust agencies’ focus on health care. We also report on an EU fine for cross-border trade restrictions, the European Commission’s antitrust position on labor market practices, updates on sustainability initiatives and more.
Antitrust in focus May 2024
aoshearman.smh.re
-
Our latest edition of Antitrust in focus, edited by David Higbee and Dominic Long, tells you about the U.K.’s new consumer, antitrust and digital markets regime, scrutiny of serial acquisitions and below-threshold deals, and the U.S. antitrust agencies’ focus on health care. We also report on an EU fine for cross-border trade restrictions, the European Commission’s antitrust position on labor market practices, updates on sustainability initiatives and more.
Antitrust in focus May 2024
aoshearman.smh.re
-
Global Co-Head of Technology at A&O Shearman | Technology, fast growth and disruption
Our latest edition of Antitrust in focus, edited by David Higbee and Dominic Long, tells you about the U.K.’s new consumer, antitrust and digital markets regime, scrutiny of serial acquisitions and below-threshold deals, and the U.S. antitrust agencies’ focus on health care. We also report on an EU fine for cross-border trade restrictions, the European Commission’s antitrust position on labor market practices, updates on sustainability initiatives and more.
Antitrust in focus May 2024
aoshearman.smh.re
-
Part two of our article series "Patentability of Diagnostic Methods in the United States and Abroad," published by the Intellectual Property and Technology Law Journal, provides parameters for subject matter eligibility of diagnostic methods in jurisdictions outside the United States, which may guide applicants and practitioners. Read the article to learn more. https://gag.gl/OMkCG5 Authors: Haley Ball, PhD, Shoshana Marvin, and Gaby L. Longsworth #DiagnosticMethods #Patentability #IntellectualProperty
Patentability of Diagnostic Methods in the United States and Abroad – Part II | Sterne Kessler
sternekessler.com
